Australia · Delayed Price · Currency is AUD PYC Therapeutics Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease.
PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.
The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019.
PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
| Country | Australia |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Rohan Hockings |
Contact Details
Address: Harry Perkins Inst. of Medical Research Nedlands, 6009 Australia | |
| Phone | 61 8 6151 0992 |
| Website | pyctx.com |
Stock Details
| Ticker Symbol | PYC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PYC7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | Chief Executive Officer and Executive Director |
| Andrew Taylor B.Com., C.A. | Chief Financial Officer and Company Secretary |
| Dr. Sri Mudumba | Chief Research and Development Officer |
| Dr. Paula Cunningham | Chief Pre-Clinical Research Officer |
| Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary |